As I am reading this thread of messages (ignoring all the bashing) I am failing to see anybody speaking of the neauromodualtion pain mangement technology that came to BSX in this deal. My understanding is that is what they BSX mangement) really wanted. The growth potential for stimulation of certain nerve ends in the spinal cord to manage back pain. Come on, everyone on here probably knows someone who suffers from chronic back pain. THe growth potential is in that part of the business. Am I missing something. I realize I am opening the door to get myself bashed but I am trying to learn something.
In 2004 BSX had predicted that Advanced Bionics would reach $4 billion in sales by 2010. If you add up the sales from the piece that BSX has (neuromod, $245 million) and Al Mann (auditory, $117 million), that comes out to $362 million in 2008. I doubt that sales will grow by $3.6 billion in 2 years. Once again, Tobin's predictions were way off!